Avalyn Pharma has drawn in another fundraising round, this time a $100 million oversubscribed series D to continue developing ...

Roche’s IgG2 monoclonal antibody (mAb) astegolimab has yielded mixed results in chronic obstructive pulmonary disease (COPD), ...

The pivotal Phase IIb ALIENTO study met the primary endpoint of a statistically significant reduction in the annualized exacerbation rate (AER) at 52 weeks ...

Trelegy Ellipta, a triple-therapy inhaler containing an inhaled corticosteroid (ICS), a long-acting muscarinic antagonist (LAMA), and a long-acting beta-agonist (LABA), was found to offer ...

They were allowed to be on monotherapy or dual therapy during the year before cohort entry, but were excluded if they had received either study inhaler or an inhaled corticosteroid-LAMA-LABA ...

Consider patient characteristics when making treatment decisions Triple therapy of an inhaled corticosteroid, long acting β2-agonist (LABA), and long acting muscarinic antagonist (LAMA) is more ...

Verona's approval of ensifentrine in COPD offers promising potential with its MoA and safety profile in a competitive market. Read my analysis of VRNA stock.

Triple therapy in COPD involves long-acting β2-agonist, long-acting muscarinic antagonist, and inhaled corticosteroid (LABA/LAMA/ICS).

Researchers assessed how the type of inhaler treatment used by patients with COPD affected the occurrence of cardiovascular events.

These results were overall consistent with findings from the 2016 FLAME trial. Bottom line: A large retrospective cohort study demonstrated fewer COPD exacerbations and pneumonia hospitalizations for ...

A generic fluticasone-salmeterol (Wixela Inhub) maintenance inhaler was clinically equivalent to name-brand Advair Diskus for chronic obstructive pulmonary disease (COPD), a propensity score ...